Table 1 Patient characteristics at baseline. All characteristics reported in the table were determined at inclusion in the AKIKI or IDEAL-ICU trial, or before initiation of renal replacement therapy*
Characteristic | Before weighting | After inverse probability weighting | ||||||
|---|---|---|---|---|---|---|---|---|
Total (n = 543) | CRRT group (n = 269) | IHD group (n = 274) | SMD (%) | CRRT group (n = 268.2) | IHD group (n = 271.9) | SMD (%) | p value | |
Age, years | 66.5 (13.3) | 66.2 (13.4) | 66.8 (13.3) | 4.4 | 66.5 (13.4) | 66.7 (13.2) | 1.5 | 0.87 |
Female sex | 200 (36.8%) | 101 (37.6%) | 99 (36.1%) | 2.9 | 97.4 (36.3%) | 101.2 (37.2%) | 1.9 | 0.83 |
Serum creatinine before ICU admission, µmol/L* | 86.2 (34.1) | 84·6 (36.7) | 87.8 (31.3) | 9.4 | 86.6 (33.8) | 86.8 (32.1) | 0.6 | 0.95 |
Coexisting conditions | ||||||||
Chronic kidney disease | 54 (9.9%) | 23 (8.6%) | 31 (11.3%) | 9.3 | 24.3 (9.1%) | 30.6 (11.3%) | 7.2 | 0.43 |
Chronic hypertension | 301 (55.4%) | 136 (50.6%) | 165 (60.2%) | 19.5 | 148.4 (55.4%) | 153.3 (56.4%) | 2.0 | 0.82 |
Diabetes mellitus | 109 (20.1%) | 55 (20.4%) | 54 (19.7%) | 1.8 | 53.7 (20.0%) | 53.5 (19.7%) | 0.9 | 0.92 |
Congestive heart failure | 43 (7.9%) | 22 (8.2%) | 21 (7.7%) | 1.9 | 21.6 (8.1%) | 22.2 (8.2%) | 0.4 | 0.97 |
Cirrhosis | 53 (9.8%) | 27 (10.0%) | 26 (9.5%) | 1.8 | 26.3 (9.8%) | 25.1 (9.2%) | 2.0 | 0.82 |
Respiratory disease | 62 (11.4%) | 30 (11.2%) | 32 (11.7%) | 1.7 | 30.4 (11.3%) | 31.3 (11.5%) | 0.5 | 0.95 |
Cancer | 89 (16.4%) | 48 (17.8%) | 41 (15.0%) | 7.8 | 43.2 (16.1%) | 43.2 (15.9%) | 0.6 | 0.95 |
AIDS | 5 (0.9%) | 3 (1.1%) | 2 (0.7%) | 4.0 | 3.1 (1.1%) | 4.0 (1.5%) | 2.8 | 0.79 |
Immunosuppressive drugs | 32 (5.9%) | 21 (7.8%) | 11 (4.0%) | 16.1 | 15.3 (5.7%) | 14.0 (5.2%) | 2.4 | 0.79 |
Organ transplantation | 5 (0.9%) | 4 (1.5%) | 1 (0.4%) | 11.7 | 2.6 (1.0%) | 2.6 (1.0%) | < 0.1 | 0.99 |
SOFA score at inclusion (0 to 24) | 11.4 (3.2) | 11.7 (3.1) | 11.1 (3.3) | 18.6 | 11.5 (3.2) | 11.4 (3.2) | 1.8 | 0.84 |
Renal SOFA (1 to 5) | 3.7 (1.1) | 3.6 (1.1) | 2.9 (1.2) | 4.4 | 3.7 (1.1) | 3.7 (1.1) | 0.4 | 0.97 |
Cardiovascular SOFA (1 to 5) | 4.4 (1.3) | 4.6 (1.1) | 4.3 (1.4) | 24.6 | 4.5 (1.2) | 4.4 (1.3) | 2.5 | 0.78 |
Liver SOFA (1 to 5) | 1.8 (1.1) | 1.8 (1.1) | 1.8 (1.1) | 4.0 | 1.8 (1.1) | 1.8 (1.1) | 3.1 | 0.73 |
Neurologic SOFA (1 to 5) | 2.2 (1.5) | 2.2 (1.5) | 2.3 (1.5) | 6.8 | 2.2 (1.5) | 2.2 (1.5) | 0.4 | 0.96 |
Coagulation SOFA (1 to 5) | 3.2 (1.6) | 3.0 (1.6) | 3.3 (1.6) | 17.3 | 3.2 (1.6) | 3.1 (1.6) | 2.1 | 0.81 |
Body weight, kg | 82.0 (21.9) | 81.1 (21.9) | 83.0 (21.9) | 8.8 | 83.0 (23.5) | 82.3 (21.9) | 3.3 | 0.73 |
Laboratory values | ||||||||
Serum creatinine, µmol/L | 286.6 (126.9) | 273.7 (122.5) | 299.3 (130.0) | 20.3 | 287.5 (129.1) | 290.2 (124.0) | 2.1 | 0.82 |
Serum urea, mmol/L | 19.8 (9.1) | 19.4 (9.0) | 20.3 (9.2) | 10.1 | 19.8 (9.0) | 20.0 (9.0) | 1.5 | 0.87 |
Serum potassium, mmol/L | 4.38 (0.77) | 4.41 (0.78) | 4.35 (0.76) | 8.3 | 4.38 (0.77) | 4.38 (0.79) | 0.5 | 0.96 |
Arterial blood pH | 7.30 (0.10) | 7.30 (0.10) | 7.30 (0.09) | 4.3 | 7.30 (0.10) | 7.30 (0.10) | 1.3 | 0.89 |